An independent valuation from a major global accounting firm has assessed the fair value of NewGen’s acquired IP at US$17.9 million, increasing NAV per share by approximately US$8.9.
The acquisition is expected to facilitate NewGen’s shift from an IVF services provider to a technology-focused innovator.
BANGKOK, Oct. 06, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), an Asian fertility services provider, announced the results of an independent valuation report (the “Report”) from a leading global accounting firm regarding its recently acquired advanced cytometry intellectual property (the “IP”), initially announced on July 29, 2025. The Report values the IP at US$17.9 million. Including the value of associated equipment and assets, the acquisition resulted in an immediate Bargain Purchase Gain of US$19.2 million and increased the Company’s Net Asset Value (“NAV”) by around US$8.9 per share as of today. This gain should significantly improve the company’s year-end net profit.
The IP is related to advanced cytometry technology acquired by NewGen. This acquisition marks a significant strategic change, transitioning NewGen from traditional IVF services to a technology-driven service model. Utilizing this patented platform, NewGen anticipates generating high-margin, recurring revenue through a capital-light model. This includes technology licensing, royalty collection, and supplying proprietary consumables to fertility clinics, providing partners with advanced solutions without upfront investment to improve their services and outcomes.
To strengthen its position as a technology leader in fertility services, NewGen is seeking all necessary regulatory approvals for commercialization. It will also establish an in-house research and development team to drive innovation and maintain a competitive edge. This creates a protected growth opportunity and a new path for scalable expansion. With the global fertility services market growing, particularly in Asia Pacific, this technology allows NewGen to capture significant market share in a sector where 1 in 6 couples globally experience infertility.
Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, stated, “This demonstrates our ability to identify and capitalize on accretive opportunities in fertility technology. By acquiring this IP below fair market value, we’ve immediately increased shareholder value and strengthened our capabilities. This positions NewGen as a technology leader, providing advanced solutions and hardware to fertility providers globally, creating a sustainable growth model through royalty-based revenue and cost advantages.”
About NewGen
NewGen provides comprehensive fertility services in Asia, helping couples and individuals access fertility treatments. Committed to assisting individuals in building families, NewGen focuses on increasing access to infertility treatment and providing comprehensive fertility services. The management team has over a decade of experience in the industry. NewGen’s clinics, located in Thailand, Cambodia, and Kyrgyzstan, offer a full suite of services, including infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. More information is available at . The information on NewGen’s website is not part of this press release.
Forward-Looking Statements
This release includes forward-looking statements made under the U.S. Private Securities Litigation Reform Act of 1995’s safe harbor provisions. These statements are often identified by terms like “believe,” “project,” “expect,” and similar expressions. They include descriptions of financial results and business strategy. These statements are predictions based on current expectations and assumptions, and are subject to risks and uncertainties. Many factors could cause actual events to differ, including the ability to generate revenue, license technology, collect royalties, and supply consumables. Consider these factors and the risks in the Company’s Form 20-F and other SEC filings, which could cause differences in actual events and results. These documents are available on the SEC’s website, www.sec.gov. All information is current as of this release date, and the Company does not update statements unless required by law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
“`